Company news

Equillium, Inc. news in 2026

Equillium, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Equillium Announces First Subject Dosed in Phase 1 Clinical Trial of EQ504

October 26, 2026

Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference

October 6, 2026

Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504

October 5, 2026

Equillium Announces Poster Presentations at the 7th International AHR Conference

September 29, 2026

Equillium to Participate in Stifel’s 2026 Virtual Immunology and Inflammation Forum

September 16, 2026

Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

August 13, 2026

Equillium Reports Inducement Grants under Nasdaq Listing Rule 5635(4)

June 3, 2026

Equillium to Participate in the 2026 Jefferies Global Healthcare Conference

May 27, 2026

Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis

May 20, 2026

Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights

May 12, 2026

Equillium to Participate in Oppenheimer’s 2026 Innovation on the Island Event

April 20, 2026

Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists

April 7, 2026

Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights

March 24, 2026

Equillium to Participate in the 38th Annual Roth Conference

March 17, 2026

Equillium Announces $35 Million Financing with RA Capital Management

March 12, 2026

Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference

February 25, 2026

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 2, 2026

Decks in 2026